האיחוד האירופי - לטבית - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - cukura diabēts - cukura diabēts - cukura diabēta ārstēšana.

לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

bela-pharm gmbh&co.kg, vācija - borskābe,kalcija glikonāts,magnija hlorīda heksahidrāts - šķīdums infūzijām - aitas; cūkas; kazas; liellopi; zirgi

לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

kon-pharma gmbh, vācija - kalcija glikonāts, magnija hlorīda heksahidrāts, kalcija glicerofosfāts - šķīdums injekcijām - cūkas; liellopi; zirgi

לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

kon-pharma gmbh, vācija - kalcija glikonāts, magnija hlorīda heksahidrāts, kalcija glicerofosfāts - šķīdums injekcijām - cūkas; liellopi; zirgi

האיחוד האירופי - לטבית - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiski līdzekļi - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. papildinformāciju par cilvēka epidermas augšanas faktora 2 receptora (her2) statusu, lūdzu, skatiet 5. sadaļā. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. sīkāku informāciju par her2 statusu, lūdzu, skatiet 5. sadaļā. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

bioveta, a.s., Čehija - suņu parainfluenza vīruss, celms cpiv2-bio15, suņu adenovīrusa tips 2, celms, cav2-bio 13, suņu parvovīrusa tips 2, celms, cpv-2b-bio-12/b suņiem, distemper virus, celms cdv bio 11/a - liofilizāts un šķīdinātājs suspensijas injekcijām pagatavošanai - suņi

לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

boehringer ingelheim pharma gmbh & co. kg, vācija - inaktivēta cūku reproduktīvais un respiratorais sindroms vīruss, celms 94881 - liofilizāts un šķīdinātājs suspensijas injekcijām pagatavošanai - cūkas

לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

ceva sante animale,, francija - cefalonijs - suspensija ievadīšanai tesmenī - 250 mg - cietstāvošas govis

לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

lavet pharmaceuticals ltd., ungārija - doxycyclin hyclate - pulveris iekšķīgi lietojama šķīduma pagatavošanai - cūkas; tītari; vistas

לטביה - לטבית - Pārtikas un veterinārais dienests, Zemkopības ministrija

huvepharma nv, beļģija - paromomicīns sulfāts - pulveris lietošanai ar dzeramo ūdeni, pienu vai piena aizvietotāju - 70 mg/g - cūkas; teļi pirms atgremošanas procesu sākšanās